Cynthia Matossian discusses some of the new pharmaceutical products that are available for dry eye disease, including Restasis®, XiidraTM (lifitegrast), CequaTM (cyclosporine), and Klarity-C Drops® that are available on prescription when dry eye disease patients present with inflammation.
Hot Topics – What pharmaceutical products beat dry eye disease?
Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
The Boston Keratoprosthesis type II (BK2) device may be the only viable option to salvage vision in patients with severe cicatrizing ocular surface disease. The prior BK2 model was modified to the present day (click-on) model in 2009. The clinical outcomes of the current click-on BK2 model is discussed in this touchOPHTHALMOLOGY interview with Dr […]
Mark CompleteCompleted
BookmarkBookmarked
It was a pleasure to interview Marie Bannier-Hélaouët (Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences, Utrecht, Netherlands) about her fascinating research into lachrymal gland organoids, which have great potential for the future treatment of lachrymal gland ...
Mark CompleteCompleted
BookmarkBookmarked
NEW
Jennifer Loh (South Florida Vision Associates, Fort Lauderdale, Florida, USA) discusses unmet needs in the treatment of dry eye, and gives an overview of the TearCare system and the efficacy and safety findings of the OLYMPIA clinical trial. Questions: 1. What ...
Mark CompleteCompleted
BookmarkBookmarked
Cynthia Matossian discusses the latest technological and pharmaceutical advancements that are easing the burden of administering eye drops, both for patients and their caregivers.
Mark CompleteCompleted
BookmarkBookmarked
Cynthia Matossian discusses intense pulsed light (IPL), a new treatment for meibomian gland dysfunction, which is one of the causes of dry eye disease.
Mark CompleteCompleted
BookmarkBookmarked
Cynthia Matossian discusses the procedures and tools that are currently available to treat dry eye disease associated with meibomian gland dysfunction, including LipiFlow® from Johnson and Johnson, TearCare® (Sight Sciences), and EyeLocks from Alcon.
Mark CompleteCompleted
BookmarkBookmarked
We met with Christina Grupcheva at ESCRS 2019 in Paris to talk about the unmet needs in the diagnosis and treatment of dry eye disease and how the landscape is evolving. Questions: 1. What are the current unmet needs in dry eye ...
Mark CompleteCompleted
BookmarkBookmarked
Prof. Leonardi discusses his experiences working on educational programs for Santen, his experiences with cyclosporine, and the highlights from the Santen-sponsored satellite symposium at the SOE 2019, ‘Long-term solutions in dry eye disease.’ 1. Describe your experiences working with Santen’s Educational ...
Mark CompleteCompleted
BookmarkBookmarked
Stephen Pflugfelder discusses the important topic of definitions in dry eye disease, and why it's important for ophthalmologists to have a clear definition of the disease. 1. How is dry eye disease currently defined? (0:04) 2. Why do we need a new definition ...
Mark CompleteCompleted
BookmarkBookmarked
At this year’s AAO meeting, we met up with Dr Eduardo Alfonso and got his insight on the hot topics being discussed at the congress. Dr Alfonso highlights some of the key messages from the session he chaired, including ...
Mark CompleteCompleted
BookmarkBookmarked
We met up with Editorial Board member Bennie Jeng, who updated us on the exciting recent developments in dry eye disease and several new therapies are in development in the US. Dr Jeng talked about his experience with scleral contact ...
Mark CompleteCompleted
BookmarkBookmarked
Rolando and Melissa Toyos talk about their current research into intense pulse light (IPL) therapy for dry eye disease. IPL therapy is a light treatment applied to the skin to stimulate the meibomian glands to produce a better tear. The ...
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
